ecrin-mdr-crcClinical2023IPD Sharing (as of August 2023): NoColorectal cancerColorectal NeoplasmsColorectal Cancer MetastaticColorectal CancerColorectal NeoplasmsColorectal Cancer MetastaticInterventionalhttps://newmdr.ecrin.org/Study/90532China5FruquintinibECRIN MDRRecruitingfalseEfficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II StudyThe overall 5-year survival rate for patients with colorectal liver metastases (CRLM) is still less than 20%. Surgery-based local treatment can achieve no evidence of disease (NED) in CRLM patients, but over 60% of patients experience recurrence even after achieving NED. Even with adjuvant therapy for the 6-month perioperative period after achieving NED, the recurrence rate remains high. Fruquintinib is a selective anti-angiogenic inhibitor that may help reduce tumor recurrence and prolong the time to recurrence and metastasis. The Chinese Society of Clinical Oncology (CSCO) guidelines have recommended fruquintinib as a third-line therapy for colorectal cancer. This study aims to evaluate the effectiveness and safety of fruquintinib as a maintenance therapy for patients with advanced colorectal cancer (CRC) who have achieved no evidence of disease (NED) after completing adjuvant chemotherapy.2023-05-1590532NCT06018714